BioVie Inc.

BIVI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $9.0M $17.5M $23.8M $19.5M $18.6M $4.5M $37.2K —
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $13.6M $20.7M $24.0M $34.0M $18.8M $4.6M $413.0K $674.1K
Property, Plant & Equipment — — — — — — — —
Goodwill $345.7K $345.7K $345.7K $345.7K $345.7K $345.7K $345.7K $345.7K
Intangible Assets (Excl. Goodwill) — $178.3K $407.7K $637.1K $866.5K $1.1M $1.3M $1.6M
Total Assets $14.3M $21.6M $25.2M $35.1M $20.1M $6.0M $2.1M $2.6M
Liabilities
Accounts Payable $3.7M $2.2M $3.6M $3.5M $2.4M $996.4K $1.3M $443.5K
Total Current Liabilities $3.8M $2.3M $9.4M $14.5M $4.2M $996.4K $23.5M $443.5K
Long-Term Debt — — — — — — $62.5K —
Total Liabilities $4.0M $2.6M $9.7M $19.8M $16.4M $996.4K $23.6M $443.5K
Stockholders' Equity
Retained Earnings $-374.3M $-352.1M $-334.2M $-301.2M $-251.0M $-224.9M $-41.0M $-7.3M
Total Stockholders' Equity $10.3M $19.0M $15.5M $15.3M $3.7M $5.1M $-21.5M $2.1M
← Newer Page 1 of 2 Older →